BHC Stock Up on Q3 Earnings Beat, Salix and Solta Drive Sales

Bausch Health (BHC) reported stronger-than-expected third-quarter 2025 results, with adjusted EPS of $1.16 and total revenues of $2.68 billion both surpassing consensus estimates, leading to a 7.3% after-market share increase. The positive performance was largely driven by robust growth in the Salix segment, specifically a 16% rise in Xifaxan sales, and a 25% increase in Solta Medical revenues. Consequently, the company raised the lower end of its 2025 revenue guidance to $10.050-$10.250 billion, despite its substantial $21 billion long-term debt remaining a key financial consideration.

Analysis

Bausch Health (BHC) reported a strong third quarter for 2025, with adjusted EPS of $1.16 surpassing the Zacks Consensus Estimate of $1.07 and total revenues of $2.68 billion exceeding the $2.6 billion forecast. This performance led to a 7.3% increase in shares during after-market trading and prompted the company to raise the lower end of its 2025 revenue guidance to $10.050-$10.250 billion. Organic revenue growth stood at 5% year-over-year.

The positive results were primarily driven by robust performance in the Salix and Solta Medical segments. Salix revenues grew 12% year-over-year to $716 million, with Xifaxan sales jumping 16% due to strong underlying demand, while Solta Medical revenues surged 25% to $140 million, fueled by growth across all geographies, particularly Asia Pacific. Conversely, International revenues declined 2% and certain products like Relistor and Trulance faced headwinds from unfavorable net pricing and lower volumes.

Strategic developments include the acquisition of DURECT Corporation, which enhances BHC's R&D capabilities and pipeline, notably with Larsucosterol receiving FDA Breakthrough Therapy Designation. Despite these operational and strategic advancements, the company's substantial long-term debt of $21 billion as of September 30, 2025, remains a significant financial overhang, contrasting with its $1.3 billion cash balance. This debt burden has contributed to BHC's 26.8% year-to-date stock decline, underperforming the industry's 6.2% growth.

Key Decisions for Investors

• Investors should closely monitor the sustainability of growth in key segments like Salix and Solta Medical, particularly Xifaxan sales, to gauge ongoing operational momentum
• Evaluate the company's strategy for addressing its substantial $21 billion long-term debt, which remains a significant financial overhang
• Consider the potential impact of pipeline advancements, such as Larsucosterol's Breakthrough Therapy Designation, on future revenue streams and long-term valuation
• Assess BHC's relative performance against industry peers, noting its year-to-date underperformance despite the recent Q3 earnings beat and raised guidance